Evidence map›Paper›PMID 34646064›Full record

ArticleClinical Medicine Insights. Oncology2021

Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer.

Yun-Xin Zhao, Guang-Li Yao, Jian Sun, Xiao-Lian Wang, Ying Wang, Qiu-Qiong Cai, Hui-Li Kang, Li-Ping Gu, Jia-Shun Yu, Wen-Min Li and 4 more

Open access · goldAbstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yun-Xin ZhaoDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Guang-Li YaoDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Jian SunDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Xiao-Lian WangDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Ying WangDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Qiu-Qiong CaiDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Hui-Li KangDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Li-Ping GuDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Jia-Shun YuDepartment of Urology, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Wen-Min LiDepartment of Urology, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Bei ZhangDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Jian WangDepartment of Urology, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Jiang-Jun MeiDepartment of Ultrasound, Zhoupu Hospital, Shanghai Medical College, Shanghai, China.ORCID https://orcid.org/0000-0002-0568-0653
Yi JiangDepartment of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Punan Hospital · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is valuable to predict the time to the development of castration-resistant prostate cancer (CRPC) in patients with advanced prostate cancer (PCa). This study aimed to build and validate a nomogram incorporating the clinicopathologic characteristics and the parameters of contrast-enhanced ultrasonography (CEUS) to predict the time to CRPC after androgen deprivation therapy (ADT).

methodsPatients with PCa were divided into the training (n = 183) and validation cohorts (n = 37) for nomogram construction and validation. The clinicopathologic characteristics and CEUS parameters were analyzed to determine the independent prognosis factors and serve as the basis of the nomogram to estimate the risk of 1-, 2-, and 3-year progress to CRPC.

resultsT stage, distant metastasis, Gleason score, area under the curve (AUC), prostate-specific antigen (PSA) nadir, and time to PSA nadir were the independent predictors of CRPC (all

conclusionsThe established nomogram including regular prognostic indicators and CEUS obtained an improved accuracy for the prediction of the time to CRPC. It was also applicable for early prediction of CRPC when it excluded posttreatment PSA, which might be helpful for individualized diagnosis and treatment.

Indexed as

androgen deprivation therapyCastration-resistant prostate cancercontrast-enhanced ultrasonographynomogramprostate-specific antigen

Identifiers

PMID34646064
PMCPMC8504687
OpenAlexW3206703072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.